STAT May 22, 2024
Helen Branswell

If the H5N1 bird flu virus ever acquires the ability to transmit easily to and among people — keep your fingers crossed that it doesn’t — the world is going to need serious amounts of vaccine. Like, lakes of the stuff.

Some manufacturers have been working with H5N1 viruses for years, producing small batches of doses that have undergone preliminary human testing. Some millions of doses — in the low double digits — have even been stockpiled by the U.S. government.

But deciding when to start producing H5 vaccine at scale, in the quantities needed to vaccinate the world, is no easy feat. It’s a high-cost, high-risk endeavor. Get it right and you save lives. Hesitate, and lives will be...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Opinion: The FDA needs to embrace phage therapy to help fight antimicrobial resistance
Timothy Garvey, MD: Drivers of Differences in Weight Loss with Incretins Based on Diabetes Status
J&J acquires immune disease biologics company for $850M
FDA Approves Sarepta Gene Therapy, But Only After Top FDA Official Bucks Agency Staff
Chimps’ self-medication with plants could aid drug discovery

Share This Article